Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC Flu
- Development stage
- Phase 4
- Lead developer
- GC Biopharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GC Flu is a trivalent influenza vaccine developed by Green Cross Corporation. It is administered intramuscularly and is designed to induce immunity against three different strains of the influenza virus. Clinical trials have investigated its efficacy (immunogenicity) and safety, as well as lot-to-lot consistency for its injection and pre-filled syringe formulations.
- Brand names
- GC FLU®
- Other names
- GC Flu(Trivalent)GC FLU® InjectionGC FLU® Pre-filled Syringe Injection
02
Targets
Flu (Influenza surface proteins)
Beyond the preview
Go deeper on GC Flu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC Flu.